| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial intelligence (AI) | 73.05 | 5271 |
| Intrinsic value (DCF) | 0.00 | -100 |
| Graham-Dodd Method | n/a | |
| Graham Formula | n/a |
Accuray Incorporated (NASDAQ: ARAY) is a global leader in precision radiation oncology solutions, specializing in advanced radiosurgery and radiation therapy systems for tumor treatment. The company’s flagship products include the CyberKnife System, a robotic stereotactic radiosurgery platform, and the TomoTherapy System (including Radixact), which integrates treatment planning, delivery, and data management for high-precision radiation therapy. Serving hospitals and standalone treatment centers worldwide, Accuray operates across North America, Europe, Asia-Pacific, and emerging markets. With a focus on innovation, the company enhances cancer care through ultra-precise, non-invasive treatments, supported by its proprietary iDMS data management and Accuray precision treatment planning systems. Founded in 1990 and headquartered in Madison, Wisconsin, Accuray continues to expand its footprint in the $6B+ radiation therapy market, driven by rising cancer incidence and demand for cost-effective, patient-centric solutions.
Accuray presents a high-risk, high-reward opportunity in the radiation therapy sector. Its niche focus on robotic and adaptive radiotherapy systems (CyberKnife, Radixact) differentiates it from conventional linear accelerator providers, but the company faces challenges, including consistent profitability (net loss of $15.5M in FY2023) and competitive pressure from larger medtech players. ARAY’s $161M market cap reflects its speculative profile, though its technology could benefit from increasing adoption of hypofractionated and stereotactic treatments. Key risks include reliance on capital equipment sales (lumpy revenue cycles), debt of $210M against $68.6M cash, and exposure to hospital spending delays. However, with a beta of 1.3, ARAY offers leveraged exposure to oncology innovation—making it a tactical pick for growth investors comfortable with volatility.
Accuray competes in the radiation therapy market by emphasizing precision and workflow efficiency, particularly for complex cases (e.g., spinal or lung tumors). Its CyberKnife System’s robotic mobility and real-time tumor tracking provide a unique advantage over fixed gantry systems like Varian’s TrueBeam. However, the company lacks the scale of diversified rivals—its $446M revenue pales against Elekta’s $1.8B or Varian’s (now Siemens Healthineers’) $3.4B in radiation oncology sales. ARAY’s TomoTherapy differentiates via helical delivery (vs. conventional IMRT), but Siemens and Elekta dominate with broader product portfolios and stronger service networks. ARAY’s cost-effective systems appeal to mid-tier hospitals, but its limited R&D budget ($47M annually vs. Siemens’ $1B+) challenges long-term innovation. The company’s direct+distributor hybrid model aids international reach but struggles against rivals’ entrenched relationships. Competitive moats include 550+ CyberKnife installations (network effects) and proprietary Adaptive Targeting algorithms, though reimbursement pressures and consolidation among providers (favoring bundled solutions) remain headwinds.